Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT05897333
Recruiting Observational

Turkish Isolated Coronary Ectasia Registry: The T-ICE Registry

NCT05897333 · tracked via the Priya Life Science Turkey tracker
Sponsor
Gazi University
Phase
Observational
Started
2022-03-15
Last updated
2023-06-09

Condition(s) studied

Coronary Artery Disease

Study summary

The T-ICE study is a prospective, observational study aiming to have information about the treatment and long-term prognosis of patients with isolated coronary artery ectasia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Isolated coronary artery ectasia (without ≥20% stenosis in any coronary artery ≥2 mm in diameter). * All patients with isolated coronary ectasia with or without acute coronary syndrome will be included. * Patients aged ≥18 years. * Patients with discrete coronary artery aneurysm will be included. Exclusion Criteria: * Life expectancy \<24 months * Patients with ≥20% stenosis in a vessel ≥2 mm in diameter.

Primary outcome measure(s)

  • Major adverse cardiovascular and cerebrovascular events — Five years
    A composite endpoint of death, myocardial infarction, unstable angina, stroke, and coronary revascularization.

Trial sites (1)

FacilityCityRegionStatus
Gazi University, School of Medicine Ankara Turkey (Türkiye) Recruiting

More Gazi University trials in Turkey

Clinical Results of Arthroscopic-Assisted Lower Trapezius Tendon Transfer for Massive, Irreparable Rotator Cuff Tears Active, not recruiting
The Effect of Art-Based Intervention on Fatigue, Anxiety, Perception of Nurse Presence, and Quality of Life in Patients With Hematological Cancers Starting soon
Investigation of the Effects of Task-Oriented Circuit Training on Upper Extremity Motor Function in Stroke Patients Recruiting
Effects of Cognitive Dual-Task on Gait in Parkinson's Disease Starting soon
Acute Effects of Functional Inspiratory Muscle Training in Elite Male Volleyball Players Recruiting

Other trials for the same condition

Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention Active, not recruiting
Recto-intercostal Block for Coronary Artery Bypass Grafting Active, not recruiting
Radial Access Data in Vascular Interventions Registry Recruiting
DECisive Intracoronary PHysiology and Imaging in the Evaluation and Reclassification of Non-culprit Lesions in Acute Coronary Syndrome Active, not recruiting
Guided Visualization Meditation for Reducing Surgical Stress Response in Cardiac Surgery Patients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05897333 on ClinicalTrials.gov ↗ ← All trials in Turkey